טוען...
Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
Suppression of gonadal testosterone synthesis represents the standard first line therapy for treatment of metastatic prostate cancer. However, in the majority of patients who develop castration-resistant prostate cancer (CRPC), it is possible to detect persistent activation of the androgen receptor...
שמור ב:
| Main Authors: | , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Medknow Publications & Media Pvt Ltd
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4023364/ https://ncbi.nlm.nih.gov/pubmed/24759590 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/1008-682X.129133 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|